US HEALTHCARE PROFESSIONAL SITEFOR US PATIENTS & CAREGIVERS

On this page:

Downloadable resources

BEQALZI Patient Brochure

Use this resource to help you through your journey and guide conversations with your healthcare provider.

Download

BEQALZI Patient Dosing Guide

Use this convenient resource with helpful information as you get started on BEQALZI.

Download

Patient Support

The myBeOne Support program pairs eligible patients with a dedicated Oncology Nurse Advocate who can help personalize support throughout your treatment with BEQALZI.

Program services include:

  • Simplifying access
    • Assessment of insurance coverage
    • Bridge supply during insurance coverage delays*
    • Co-pay support for commercially insured patients*
    • Free medication for uninsured and underinsured patients*
  • Education about BEQALZI

    Along with your healthcare team, your Oncology Nurse Advocate can help answer questions you may have about treatment with BEQALZI.

  • Providing personalized
    solutions

    Living with cancer takes support. Your Oncology Nurse Advocate is well trained and dedicated to identifying independent organizations† that can help address your needs.

Contact the myBeOne Support program

For any questions or to help you get started, simply call 1-833-234-4363, M–F, 8 AM to 8 PM ET, to speak with an Oncology Nurse Advocate, or visit myBeOneSupport.com.

Visit myBeOne Support

*Terms and conditions apply. Up to $25,000 per calendar year.

†Independent third-party organizations have their own rules for eligibility. BeOne Medicines has no involvement in their decision-making or eligibility criteria. This information is non-exhaustive and not meant as an endorsement from BeOne Medicines.

myBeOneSupport® is not insurance and does not guarantee product coverage or reimbursement.

Cancer Community Resources

Mentions of support organizations are for general informational purposes. This page does not endorse these organizations or their services.

  • Lymphoma Research Foundation Logo

    Lymphoma Research Foundation

    The Lymphoma Research Foundation (LRF) is the nation’s largest lymphoma-focused health organization devoted to improving care through education and support services and improving outcomes through investment in the most promising lymphoma research.

    Visit Site
  • Blood Cancer United Logo

    Blood Cancer United

    Blood Cancer United funds groundbreaking research, connects people with financial assistance, offers personal one-on-one support, and advocates for policies that improve access to quality care for all blood cancer patients and their families.

    Visit Site
  • Cancer Support Community Logo

    Cancer Support Community

    The Cancer Support Community is a global nonprofit that uplifts and strengthens people impacted by cancer. They provide professionally led support and navigation services, along with social connections and award-winning education—when, where, and how impacted individuals prefer throughout their cancer experience. These resources are available at more than 200 locations in 50 markets, including Cancer Support Community and Gilda’s Club centers, healthcare partner locations, and also online and over the phone—all at no cost.

    Visit Site
  • National Comprehensive Cancer Network Logo

    National Comprehensive Cancer Network® (NCCN®)

    NCCN is a not-for-profit alliance of 33 leading cancer centers devoted to patient care, research, and education.

    Visit Site
  • CancerCare Logo

    CancerCare

    Founded in 1944, CancerCare is the leading national organization providing free, professional support services and information to help people manage the emotional, practical, and financial challenges of cancer. The comprehensive services offered by CancerCare include resource navigation, counseling, and support groups over the phone, online, and in person; educational workshops; publications; and financial and co-payment assistance. All CancerCare services are provided by master’s-prepared oncology social workers and world-leading cancer experts.

    Visit Site
  • Caregiver Action Network Logo

    Caregiver Action Network

    Caregiver Action Network (CAN) is the nation’s leading family caregiver organization. It works to improve the quality of life for tens of millions of family caregivers who care for loved ones with chronic conditions, disabilities, or diseases. CAN also supports those meeting the living needs of older adults.

    Visit Site
  • American Cancer Society Logo

    American Cancer Society

    The American Cancer Society’s mission is to improve the lives of people with cancer and their families through advocacy, research, and patient support, to ensure everyone has an opportunity to prevent, detect, treat, and survive cancer. ACS provides information, answers, and support, such as transportation and lodging, to people in every community who have been touched by cancer.

    Visit Site
  • Mantle Cell Lymphoma Alliance (MCLA) Logo

    Mantle Cell Lymphoma Alliance

    The Mantle Cell Lymphoma Alliance (MCLA) is a nonprofit organization dedicated exclusively to supporting people affected by mantle cell lymphoma through trusted information, expert-guided resources, patient and caregiver engagement, and support for research that improves outcomes.

    Visit Site

TAKING
BEQALZI

See how BEQALZI may fit into your day

Actor portrayal.

SIDE EFFECTS
AND BEQALZI

Learn about side effects you might experience with BEQALZI

Actor portrayal.

IMPORTANT SAFETY INFORMATION

BEQALZI can cause serious side effects, including:

  1. Tumor Lysis Syndrome (TLS)
    1. TLS has occurred in patients treated with BEQALZI. TLS is caused by the fast breakdown of cancer cells, which can cause kidney failure, the need for dialysis treatment, and can be life-threatening. TLS can happen when you first start treatment, with dose increases, or if treatment is restarted.
    2. Before starting BEQALZI, your healthcare provider will assess your risk for TLS. You will receive other medicines and be advised to drink plenty of fluids during your treatment course. Some patients may need hospitalization for IV fluids and closer monitoring. Blood tests will be done before and during treatment. Keep all scheduled appointments.
    3. Tell your healthcare provider right away if you develop symptoms such as nausea; vomiting; diarrhea; muscle cramps, weakness, or twitches; fatigue; decreased urination; swelling in your legs, ankles, or feet; numbness or tingling, especially around your mouth or in your hands and feet; confusion or difficulty staying alert; irregular or fast heart rate; or seizures.
    4. Drink 6 to 8 glasses (about 1.5 to 2 liters or 51-68 ounces) of water each day starting 1 to 2 days before your first dose, on the day of your first dose, during dose increases, and if treatment is restarted.

  2. Serious infections. BEQALZI can cause death or serious infections. Your healthcare provider will monitor you for signs and symptoms of infection and treat you as needed. Tell your healthcare provider right away if you develop a fever or any signs of an infection.

  3. Decreased white blood cell count (neutropenia), which can be serious or severe and increase the risk of infection. Your healthcare provider will check your blood counts during treatment and may decrease your dose, temporarily stop, or completely stop treatment if you get certain side effects.

Do not take BEQALZI with certain medicines called strong CYP3A inhibitors when starting treatment and while your dose is being increased because this may increase the risk of TLS. Other medicines, including moderate CYP3A inhibitors, may require dose changes. Tell your healthcare provider about all the medicines you take, and do not start new medicines during treatment without talking to your healthcare provider. Avoid grapefruit products, Seville oranges (often used in marmalades), and star fruit. These can increase the amount of BEQALZI in your blood.

Before taking BEQALZI, tell your healthcare provider about all of your medical conditions, including if you have kidney problems, problems with body salts or electrolytes (such as potassium, phosphorus, or calcium), or a history of high uric acid or gout. Also tell your healthcare provider if you are pregnant, plan to become pregnant, or are breastfeeding or plan to breastfeed. BEQALZI may affect male and female fertility. If you receive BEQALZI while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment and you should use effective birth control (contraception) during treatment and for 1 week after the last dose. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment and for 1 week after your last dose. Do not breastfeed during treatment and for 1 week after the last dose. If you are a male with a female partner who can become pregnant, use effective birth control (contraception) during treatment and for 1 week after the last dose.

The most common side effects of BEQALZI include pneumonia and tiredness. The most common abnormal blood tests with BEQALZI are decreased white blood cell counts.

If you have side effects, your healthcare provider may tell you to stop taking BEQALZI for a period of time. Do not restart BEQALZI on your own. Call your healthcare provider before you start taking BEQALZI again.

These are not all the possible side effects of BEQALZI. Call your healthcare provider for medical advice about side effects. You may report side effects to BeOne Medicines at 1-877-828-5596 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Please see Medication Guide.

What is BEQALZI?

BEQALZI™ (sonrotoclax) is a prescription medicine used to treat adults with mantle cell lymphoma (MCL) that has come back or did not respond to previous treatment, and who have already received 2 treatments for their cancer, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was approved based on patient response data. Studies are ongoing to confirm the clinical benefit of BEQALZI. It is not known if BEQALZI is safe and effective in children.